A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Status: | Completed |
---|---|
Conditions: | Arthritis |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 12 - 16 |
Updated: | 10/6/2017 |
Start Date: | April 2012 |
End Date: | February 2015 |
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
Inclusion Criteria:
- Parent or legal guardian is able to provide written informed consent and patient is
able to provide written assent if appropriate.
- Male and female adolescents aged 12 to 16 years at the time of enrollment.
- Diagnosed with JIA, including all the International League of Associations for
Rheumatology JIA subtypes: oligoarthritis, polyarthritis (both rheumatoid factor [RF]+
and RF-), psoriatic arthritis, enthesitis-related arthritis, undifferentiated
arthritis, and systemic arthritis.
- Based upon investigator judgment, it is determined appropriate for the patient to
undergo 6 months of continuous treatment with VIMOVO.
- Body weight > 31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass
index for age.
Exclusion Criteria:
- In systemic JIA patients, presence of systemic features (ie, fever, rheumatoid rash,
serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to
start of study drug.
- Currently taking (ie, within 4 weeks prior to start of drug) naproxen > 20 mg/kg/day
or > 1000 mg total daily dose.
- Hemoglobin ≤ 8.5 g/dL.
- Individuals who have cardiovascular or cerebrovascular disease, based on history or
risk factors.
- Any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other
medical conditions indicated by medical/surgical history, physical, or laboratory
examination that might put the patient at greater risk during the study.
We found this trial at
17
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Washington, D.C., District of Columbia
Click here to add this to my saved trials